Skip to content
Book Appointment
ApoB middle-ground — preview
Patient Resources · Cholesterol

ApoB, explained — why LDL may not tell the whole story

Dr Reza Moazzeni
Dr Reza Moazzeni, MBBS FRACP
Consultant Cardiologist · Published 14 May 2026 · Updated 25 May 2026
One particle, one ApoBApoB counts the artery-damaging particles in your blood — not the cholesterol they carry.
Medicare coveredBulk-billed when your doctor orders it. No fasting, no extra cost.
Most useful when…Triglycerides are high, there’s diabetes, or a treatment decision is finely balanced.

Your cholesterol test measures how much cholesterol you carry. ApoB counts how many particles are carrying it — and sometimes that number tells a different story.

LDL cholesterol versus ApoB — how much cholesterol versus how many particles
In one paragraph

Your cholesterol test measures how much cholesterol you carry. An ApoB test counts how many particles are carrying it. Two people with the same LDL can have very different ApoB — and the one with more particles is at higher risk. It’s most useful when triglycerides are high, when there’s a strong family history, or when a treatment decision is finely balanced.

Many patients ask me the same thing: “My cholesterol isn’t that high — so why is my doctor still worried?”

Sometimes the answer is blood pressure, diabetes, or family history. But sometimes it comes down to a number most people have never heard of: ApoB.

Here’s the short version.

LDL cholesterol tells you how much cholesterol is being carried.

ApoB tells you how many particles are carrying it.

That difference is the whole point of this article.

What is ApoB, exactly?

ApoB — apolipoprotein B — is a protein that sits on the surface of every artery-damaging cholesterol particle: LDL, VLDL, IDL, remnants, and Lp(a).

Each of those particles carries exactly one ApoB.

So measuring ApoB is really just counting particles. One ApoB, one particle.

One ApoB protein per artery-damaging particle A single LDL cholesterol particle in cross-section with one ApoB protein wrapped around its surface, above a row of five particles each carrying one ApoB. ONE PROTEIN, ONE PARTICLE A single LDL particle One ApoB protein wraps every artery-damaging particle. ApoB protein structural; one per particle Cholesterol cargo amount varies particle to particle COUNT THEM TO COUNT THE RISK …
Each artery-damaging particle carries one ApoB. Measuring ApoB counts the particles, not the cholesterol they happen to hold.

Why does that matter? Because plaque doesn’t build up when cholesterol enters the artery wall. It builds up when particles get in and get stuck.

The more particles you have, the more chances there are for one to lodge in the wall.

So how is it different from LDL cholesterol?

Think of it like traffic.

LDL cholesterol measures the total cargo on the road. ApoB counts the number of vehicles carrying it.

Two people can carry the same cargo — the same LDL — in very different numbers of vehicles.

One has a few large trucks. The other has lots of small cars. Same cholesterol, very different particle counts.

Same cholesterol carried by a few large particles versus many small particles
Same cargo, different number of vehicles — that is the ApoB idea.

And for your arteries, the number of vehicles matters more than the cargo.

What about non-HDL cholesterol?

Good question — because there is a third number on your results that does something similar.

Non-HDL cholesterol is simply your total cholesterol minus your HDL (“good”) cholesterol. It estimates the cholesterol carried in all the plaque-forming particles, not just LDL.

Non-HDL cholesterol includes the cholesterol carried in all plaque-forming particles
Non-HDL cholesterol covers all the plaque-forming particles, not just LDL.

It is a genuinely useful number. It is already on the standard lipid panel, costs nothing extra, and most of the time it tells the same story as ApoB.

The difference is subtle: non-HDL measures the amount of cholesterol in those particles. ApoB estimates the number of particles.

They usually move together. They part ways in the same situations as before — high triglycerides, type 2 diabetes, insulin resistance, metabolic syndrome, or a low HDL or LDL.

So don’t ignore non-HDL — it’s a good number, and underused. ApoB just adds more when the standard numbers don’t capture the full risk.

Can LDL cholesterol be misleading?

For most people, no. LDL and ApoB move together — if one is high, so is the other.

The issue is the people where they disagree. Lipid specialists call this discordance, and it shows up in three situations:

  • High triglycerides, diabetes, or metabolic syndrome — these make particles small and cholesterol-poor, so LDL looks fine while the particle count is high.
  • Already on a statin — statins lower LDL more than ApoB, so an “on-target” LDL can hide residual risk.
  • High Lp(a) — Lp(a) is itself an ApoB particle, so it pushes ApoB up on its own.
When LDL and ApoB disagree, risk follows the ApoB A two-by-two grid of low or high LDL cholesterol against low or high ApoB. The two high-ApoB cells are high risk regardless of LDL; the two low-ApoB cells are low risk regardless of LDL. DISCORDANCE When the two tests disagree, risk follows the ApoB Four scenarios. The number of particles (ApoB) decides the risk — not the cholesterol they carry (LDL). LOW LDL-C HIGH LDL-C HIGH APOB LOW APOB Many small particles LDL normal, particle count high ! HIGH RISK Many large particles Both numbers high — classic risk ! HIGH RISK Few small particles Both numbers low — reassuring LOW RISK Few large particles LDL high, particle count low RISK MAY BE LOWER In the two left-hand cells, LDL-C and ApoB tell different stories. The evidence shows risk follows the ApoB.
The four combinations of LDL-C and ApoB. Risk tracks with the row, not the column.
When LDL and ApoB disagree, risk follows the ApoB.

We see this in large population studies and in the big statin and PCSK9 trials (IMPROVE-IT, FOURIER, ODYSSEY OUTCOMES). The catch: those trials were built around LDL targets — so for now, ApoB refines the decision rather than replacing LDL.

When is an ApoB test actually worth it?

Not for everyone. If your LDL is normal and you have no red flags, a standard cholesterol panel is enough.

ApoB earns its place when something doesn’t add up:

Most useful

  • high triglycerides, diabetes, or metabolic syndrome
  • a strong family history of early heart disease
  • an LDL that’s “on target” on a statin, but residual risk is a worry

Sometimes useful

  • a borderline decision about whether to start treatment
  • cascade screening in families with an inherited lipid disorder
  • clarifying whether to intensify existing therapy

In those cases, ApoB can tip the decision one way or the other.

Do I need to fast? Does it cost anything?

No fasting needed — ApoB barely changes whether you’ve eaten or not.

And in Australia it’s covered by Medicare when your doctor orders it. It can be added to your usual lipid panel from the same blood draw, at no extra cost.

What’s a healthy ApoB level?

It depends on your overall risk — the higher your risk, the lower your target.

In Australia, ApoB is reported in grams per litre (g/L). Here’s a rough guide, from the 2024 National Lipid Association consensus:

Your riskApoB target
Very high — prior heart attack, stroke, stent or bypassbelow 0.6 g/L
High — diabetes with risk factors, or severe familial hypercholesterolaemiabelow 0.7 g/L
Borderline to intermediatebelow 0.9 g/L
General populationbelow 1.0 g/L
An ApoB above 1.3 g/L puts you in roughly the top 10% of adults — at that level, treatment is usually worth it whatever your LDL says.

Want to see where your own result sits? Try the ApoB converter and target tool.

How do I lower a high ApoB?

The same things that lower LDL lower ApoB — because they cut the number of particles. Lifestyle first, medication when the risk justifies it.

Lifestyle that helps:

  • Swap saturated fat (butter, fatty meat, full-fat dairy) for a Mediterranean pattern — olive oil, fish, nuts, legumes.
  • Trade refined carbs and sugary drinks for soluble fibre — oats, psyllium, beans.
  • Move most days — around 150 minutes a week.
  • If you smoke, stopping does more than any diet change.

On their own, these usually shift ApoB by about 5–15%.

When that’s not enough:

  • Statins are first line — around 30–40% lower.
  • Ezetimibe adds roughly another 15%.
  • PCSK9 inhibitors, including twice-yearly inclisiran, can add 40% or more for high-risk patients.
  • Bempedoic acid is an option if statins aren’t tolerated.

If your LDL is on target but your ApoB isn’t, that’s the exact situation where pushing treatment further pays off.

Should ApoB replace my LDL test?

Not yet. LDL is familiar, cheap, and still the number our treatment trials were built around.

Non-HDL cholesterol is also very useful, especially when triglycerides are elevated.

Think of ApoB as a sharper lens — most useful when the standard numbers don’t match the person in front of me.

The bottom line

ApoB counts particles; LDL measures cholesterol. When the two disagree, trust the particle count.

LDL and non-HDL cholesterol are both useful — ApoB just adds a sharper particle count when the standard numbers don’t match your overall risk.

If your results don’t seem to match your risk — high triglycerides, diabetes, a family history, or a borderline decision — it’s worth asking your doctor about ApoB. It’s bulk-billed, needs no fasting, and can be added to your next lipid test.

References & further reading

Clinical references
  1. Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e647–e663.
  2. Marston NA, Giugliano RP, Melloni GEM, et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction. JAMA Cardiol. 2022;7(3):250–256.
  3. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77(11):1439–1450.
  4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188.
Further reading for patients
  1. Heart Foundation (Australia) — Understanding cholesterol.
  2. Heartcare Sydney — Understanding Lp(a).
Dr Reza Moazzeni
Dr Reza Moazzeni, MBBS FRACP

Consultant cardiologist at Heartcare Sydney, Westmead — preventive cardiology, cardiovascular risk assessment, lipid disorders and cardiac imaging. Consultations in English and Persian (Farsi).

ApoB is best read alongside your full risk picture. A referral-based consultation can put your result in context.

Book an appointment